{"id":346634,"date":"2013-12-05T00:00:00","date_gmt":"2013-12-04T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/la-determination-du-statut-ras-de-la-mutation-est-importante-dans-le-mcrc\/"},"modified":"2013-12-05T00:00:00","modified_gmt":"2013-12-04T23:00:00","slug":"la-determination-du-statut-ras-de-la-mutation-est-importante-dans-le-mcrc","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/la-determination-du-statut-ras-de-la-mutation-est-importante-dans-le-mcrc\/","title":{"rendered":"La d\u00e9termination du statut RAS de la mutation est importante dans le mCRC"},"content":{"rendered":"<p><strong>Les r\u00e9sultats de l&#8217;\u00e9tude FIRE-3, pr\u00e9sent\u00e9s cette ann\u00e9e au Congr\u00e8s europ\u00e9en du cancer \u00e0 Amsterdam, soulignent l&#8217;importance et la pertinence de l&#8217;analyse des mutations RAS (KRAS et NRAS) pour la d\u00e9cision th\u00e9rapeutique en premi\u00e8re ligne. Le c\u00e9tuximab (<sup>Erbitux\u00ae<\/sup>), un anticorps monoclonal anti-EGFR, a montr\u00e9 un avantage significatif en termes de survie par rapport au b\u00e9vacizumab chez les patients atteints de tumeurs de type sauvage RAS.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>L&#8217;analyse des mutations et de l&#8217;expression permet de classer les patients atteints de cancer colorectal m\u00e9tastatique (mCRC) en diff\u00e9rents groupes : Alors que les patients pr\u00e9sentant des mutations dans les g\u00e8nes KRAS et NRAS ne sont pas \u00e9ligibles pour un traitement avec des anticorps anti-EGFR en raison de r\u00e9sistances, l&#8217;\u00e9tude FIRE-3 montre que les patients non pr\u00e9trait\u00e9s pr\u00e9sentant des tumeurs de type sauvage RAS (KRAS et NRAS) peuvent b\u00e9n\u00e9ficier d&#8217;un traitement primaire combin\u00e9 avec l&#8217;anticorps anti-EGFR c\u00e9tuximab (plus un r\u00e9gime de chimioth\u00e9rapie comprenant du 5-fluorouracil, de l&#8217;acide folinique, de l&#8217;irinot\u00e9can  [FOLFIRI]) en b\u00e9n\u00e9ficient consid\u00e9rablement : Par rapport \u00e0 la combinaison de bevacizumab (bevacizumab plus FOLFIRI), la survie globale a \u00e9t\u00e9 prolong\u00e9e de 25,6 \u00e0 33,1 mois, soit un avantage significatif de 7,5 mois en termes de survie.<\/p>\n<p>Les mutations du g\u00e8ne BRAF n&#8217;ont pas eu d&#8217;influence. La survie sans progression a \u00e9t\u00e9 comparable dans les deux groupes, soit environ dix mois.<\/p>\n<p>Ces r\u00e9sultats repr\u00e9sentent une v\u00e9ritable \u00e9tape dans le traitement par anticorps monoclonaux du mCRC. Ils constituent une \u00e9tape importante vers un traitement personnalis\u00e9 et fournissent des preuves que la d\u00e9cision th\u00e9rapeutique \u00e0 l&#8217;aide de biomarqueurs est d\u00e9j\u00e0 pertinente pour la premi\u00e8re ligne. Cela permet d&#8217;\u00e9viter des tracas inutiles sous la forme d&#8217;effets secondaires en cas de r\u00e9ponse insuffisante et de co\u00fbts \u00e9vitables.<\/p>\n<p><em>Source : Stintzig S, et al. : Pr\u00e9sentation orale \u00e0 l&#8217;ECC 2013, Abstract LBA 17<\/em><\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2013 ; 1(1) : 32<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les r\u00e9sultats de l&#8217;\u00e9tude FIRE-3, pr\u00e9sent\u00e9s cette ann\u00e9e au Congr\u00e8s europ\u00e9en du cancer \u00e0 Amsterdam, soulignent l&#8217;importance et la pertinence de l&#8217;analyse des mutations RAS (KRAS et NRAS) pour la&hellip;<\/p>\n","protected":false},"author":4,"featured_media":39170,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinome colorectal m\u00e9tastatique","footnotes":""},"category":[11414,11389,11535,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-346634","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gastro-enterologie-et-hepatologie","category-oncologie","category-rapports-de-congres","category-rx-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-17 02:33:02","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":346591,"slug":"la-determinazione-dello-stato-di-mutazione-ras-e-importante-nellmcrc","post_title":"La determinazione dello stato di mutazione RAS \u00e8 importante nell'mCRC.","href":"https:\/\/medizinonline.com\/it\/la-determinazione-dello-stato-di-mutazione-ras-e-importante-nellmcrc\/"},"pt_PT":{"locale":"pt_PT","id":346599,"slug":"determinacao-do-estado-da-mutacao-ras-e-importante-em-mcrc","post_title":"Determina\u00e7\u00e3o do estado da muta\u00e7\u00e3o RAS \u00e9 importante em mCRC","href":"https:\/\/medizinonline.com\/pt-pt\/determinacao-do-estado-da-mutacao-ras-e-importante-em-mcrc\/"},"es_ES":{"locale":"es_ES","id":346602,"slug":"la-determinacion-del-estado-de-la-mutacion-ras-es-importante-en-el-mcrc","post_title":"La determinaci\u00f3n del estado de la mutaci\u00f3n RAS es importante en el mCRC","href":"https:\/\/medizinonline.com\/es\/la-determinacion-del-estado-de-la-mutacion-ras-es-importante-en-el-mcrc\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/346634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=346634"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/346634\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=346634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=346634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=346634"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=346634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}